High-Accuracy Classification of Parkinson's Disease Through Shape Analysis and Surface Fitting in 123I-Ioflupane SPECT Imaging

Deep Convolutional Neural Networks on Multiclass Classification of Three-Dimensional Brain Images for Parkinson's Disease Stage Prediction

Parkinson's disease (PD), a degenerative disorder of the central nervous system, is commonly diagnosed using functional medical imaging techniques such as single-photon emission computed tomography (SPECT). In this study, we utilized two SPECT data sets (n = 634 and n = 202) from different hospitals to develop a model capable of accurately predicting PD stages, a multiclass classification task. We used the entire three-dimensional (3D) brain images as input and experimented with various model architectures. Initially, we treated the 3D images as sequences of two-dimensional (2D) slices and fed them sequentially into 2D convolutional neural network (CNN) models pretrained on ImageNet, averaging the outputs to obtain the final predicted stage. We also applied 3D CNN models pretrained on Kinetics-400. Additionally, we incorporated an attention mechanism to account for the varying importance of different slices in the prediction process. To further enhance model efficacy and robustness, we simultaneously trained the two data sets using weight sharing, a technique known as cotraining. Our results demonstrated that 2D models pretrained on ImageNet outperformed 3D models pretrained on Kinetics-400, and models utilizing the attention mechanism outperformed both 2D and 3D models. The cotraining technique proved effective in improving model performance when the cotraining data sets were sufficiently large.

A worldwide study of subcortical shape as a marker for clinical staging in Parkinson's disease

Alterations in subcortical brain regions are linked to motor and non-motor symptoms in Parkinson's disease (PD). However, associations between clinical expression and regional morphological abnormalities of the basal ganglia, thalamus, amygdala and hippocampus are not well established. We analyzed 3D T1-weighted brain MRI and clinical data from 2525 individuals with PD and 1326 controls from 22 global sources in the ENIGMA-PD consortium. We investigated disease effects using mass univariate and multivariate models on the medial thickness of 27,120 vertices of seven bilateral subcortical structures. Shape differences were observed across all Hoehn and Yahr (HY) stages, as well as correlations with motor and cognitive symptoms. Notably, we observed incrementally thinner putamen from HY1, caudate nucleus and amygdala from HY2, hippocampus, nucleus accumbens, and thalamus from HY3, and globus pallidus from HY4-5. Subregions of the thalami were thicker in HY1 and HY2. Largely congruent patterns were associated with a longer time since diagnosis and worse motor symptoms and cognitive performance. Multivariate regression revealed patterns predictive of disease stage. These cross-sectional findings provide new insights into PD subcortical degeneration by demonstrating patterns of disease stage-specific morphology, largely consistent with ongoing degeneration.

Radiomics incorporating deep features for predicting Parkinson's disease in 123I-Ioflupane SPECT

PURPOSE

123I-Ioflupane SPECT is an effective tool for the diagnosis and progression assessment of Parkinson's disease (PD). Radiomics and deep learning (DL) can be used to track and analyze the underlying image texture and features to predict the Hoehn-Yahr stages (HYS) of PD. In this study, we aim to predict HYS at year 0 and year 4 after the first diagnosis with combined imaging, radiomics and DL-based features using 123I-Ioflupane SPECT images at year 0.

METHODS

In this study, 161 subjects from the Parkinson's Progressive Marker Initiative database underwent baseline 3T MRI and 123I-Ioflupane SPECT, with HYS assessment at years 0 and 4 after first diagnosis. Conventional imaging features (IF) and radiomic features (RaF) for striatum uptakes were extracted from SPECT images using MRI- and SPECT-based (SPECT-V and SPECT-T) segmentations respectively. A 2D DenseNet was used to predict HYS of PD, and simultaneously generate deep features (DF). The random forest algorithm was applied to develop models based on DF, RaF, IF and combined features to predict HYS (stage 0, 1 and 2) at year 0 and (stage 0, 1 and ≥ 2) at year 4, respectively. Model predictive accuracy and receiver operating characteristic (ROC) analysis were assessed for various prediction models.

RESULTS

For the diagnostic accuracy at year 0, DL (0.696) outperformed most models, except DF + IF in SPECT-V (0.704), significantly superior based on paired t-test. For year 4, accuracy of DF + RaF model in MRI-based method is the highest (0.835), significantly better than DF + IF, IF + RaF, RaF and IF models. And DL (0.820) surpassed models in both SPECT-based methods. The area under the ROC curve (AUC) highlighted DF + RaF model (0.854) in MRI-based method at year 0 and DF + RaF model (0.869) in SPECT-T method at year 4, outperforming DL models, respectively. And then, there was no significant differences between SPECT-based and MRI-based segmentation methods except for the imaging feature models.

CONCLUSION

The combination of radiomic and deep features enhances the prediction accuracy of PD HYS compared to only radiomics or DL. This suggests the potential for further advancements in predictive model performance for PD HYS at year 0 and year 4 after first diagnosis using 123I-Ioflupane SPECT images at year 0, thereby facilitating early diagnosis and treatment for PD patients. No significant difference was observed in radiomics results obtained between MRI- and SPECT-based striatum segmentations for radiomic and deep features.

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents

Natural compounds provide precursors with various pharmacological activities and play an important role in discovering new chemical entities, including radiopharmaceuticals. In the development of new radiopharmaceuticals, iodine radioisotopes are widely used and interact with complex compounds including natural products. However, the development of radiopharmaceuticals from natural compounds with iodine radioisotopes has not been widely explored. This review summarizes the development of radiopharmaceuticals from natural compounds using iodine radioisotopes in the last 10 years, as well as discusses the challenges and strategies to improve future discovery of radiopharmaceuticals from natural resources. Literature research was conducted via PubMed, from which 32 research articles related to the development of natural compounds labeled with iodine radioisotopes were reported. From the literature, the challenges in developing radiopharmaceuticals from natural compounds were the purity and biodistribution. Despite the challenges, the development of radiopharmaceuticals from natural compounds is a golden opportunity for nuclear medicine advancement.

Explainable machine learning with pairwise interactions for the classification of Parkinson's disease and SWEDD from clinical and imaging features

Scans without evidence of dopaminergic deficit (SWEDD) refers to patients who mimics motor and non-motor symptoms of Parkinson's disease (PD) but showing integrity of dopaminergic system. For this reason, the differential diagnosis between SWEDD and PD patients is often not possible in absence of dopamine imaging. Machine Learning (ML) showed optimal performance in automatically distinguishing these two diseases from clinical and imaging data. However, the most common applied ML algorithms provide high accuracy at expense of findings intelligibility. In this work, a novel ML glass-box model, the Explainable Boosting Machine (EBM), based on Generalized Additive Models plus interactions (GA2Ms), was employed to obtain interpretability in classifying PD and SWEDD while still providing optimal performance. Dataset (168 healthy controls, HC; 396 PD; 58 SWEDD) was obtained from PPMI database and consisted of 178 among clinical and imaging features. Six binary EBM classifiers were trained on feature space with (SBR) and without (noSBR) dopaminergic striatal specific binding ratio: HC-PDSBR, HC-SWEDDSBR, PD-SWEDDSBR and HC-PDnoSBR, HC-SWEDDnoSBR, PD-SWEDDnoSBR. Excellent AUC-ROC (1) was reached in classifying HC from PD and SWEDD, both with and without SBR, and by PD-SWEDDSBR (0.986), while PD-SWEDDnoSBR showed lower AUC-ROC (0.882). Apart from optimal accuracies, EBM algorithm was able to provide global and local explanations, revealing that the presence of pairwise interactions between UPSIT Booklet #1 and Epworth Sleepiness Scale item 3 (ESS3), MDS-UPDRS-III pronation-supination movements right hand (NP3PRSPR) and MDS-UPDRS-III rigidity left upper limb (NP3RIGLU) could provide good performance in predicting PD and SWEDD also without imaging features.

fNIRS-based brain state transition features to signify functional degeneration after Parkinson's disease

OBJECTIVE

Parkinson's disease (PD) is a common neurodegenerative brain disorder, and early diagnosis is of vital importance for treatment. Existing methods are mainly focused on behavior examination, while the functional neurodegeneration after PD has not been well explored. This paper aims to investigate the brain functional variation of PD patients in comparison with healthy controls.

APPROACH

In this work, we propose brain hemodynamic states and state transition features to signify functional degeneration after PD. Firstly, a functional near-infrared spectroscopy (fNIRS)-based experimental paradigm was designed to capture brain activation during dual-task walking from PD patients and healthy controls. Then, three brain states, named expansion, contraction, and intermediate states, were defined with respect to the oxyhemoglobin and deoxyhemoglobin responses. After that, two features were designed from a constructed transition factor and concurrent variations of oxy- and deoxy-hemoglobin over time, to quantify the transitions of brain states. Further, a support vector machine classifier was trained with the proposed features to distinguish PD patients and healthy controls.

RESULTS

Experimental results showed that our method with the proposed brain state transition features achieved classification accuracy of 0:8200 and F score of 0:9091, and outperformed existing fNIRS-based methods. Compared with healthy controls, PD patients had significantly smaller transition acceleration and transition angle.

SIGNIFICANCE

The proposed brain state transition features well signify functional degeneration of PD patients and may serve as promising functional biomarkers for PD diagnosis.

Diagnosis of Parkinson syndrome and Lewy-body disease using 123I-ioflupane images and a model with image features based on machine learning

OBJECTIVES

¹²³I-ioflupane has been clinically applied to dopamine transporter imaging and visual interpretation assisted by region-of-interest (ROI)-based parameters. We aimed to build a multivariable model incorporating machine learning (ML) that could accurately differentiate abnormal profiles on ¹²³I-ioflupane images and diagnose Parkinson syndrome or disease and dementia with Lewy bodies (PS/PD/DLB).

METHODS

We assessed ¹²³I-ioflupane images from 239 patients with suspected neurodegenerative diseases or dementia and classified them as having PS/PD/DLB or non-PS/PD/DLB. The image features of high or low uptake (F1), symmetry or asymmetry (F2), and comma- or dot-like patterns of caudate and putamen uptake (F3) were analyzed on 137 images from one hospital for training. Direct judgement of normal or abnormal profiles (F4) was also examined. Machine learning methods included logistic regression (LR), k-nearest neighbors (kNNs), and gradient boosted trees (GBTs) that were assessed using fourfold cross-validation. We generated the following multivariable models for the test database (n = 102 from another hospital): Model 1, ROI-based measurements of specific binding ratios and asymmetry indices; Model 2, ML-based judgement of abnormalities (F4); and Model 3, features F1, F2 and F3, plus patient age. Diagnostic accuracy was compared using areas under receiver-operating characteristics curves (AUC).

RESULTS

The AUC was high with all ML methods (0.92-0.96) for high or low uptake. The AUC was the highest for symmetry or asymmetry with the kNN method (AUC 0.75) and the comma-dot feature with the GBT method (AUC 0.94). Based on the test data set, the diagnostic accuracy for a diagnosis of PS/PD/DLB was 0.86 ± 0.04 (SE), 0.87 ± 0.04, and 0.93 ± 0.02 for Models 1, 2 and 3, respectively. The AUC was optimal for Model 3, and significantly differed between Models 3 and 1 (p = 0.027), and 3 and 2 (p = 0.029).

CONCLUSIONS

Image features such as high or low uptake, symmetry or asymmetry, and comma- or dot-like profiles can be determined using ML. The diagnostic accuracy of differentiating PS/PD/DLB was the highest for the multivariate model with three features and age compared with the conventional ROI-based method.

An Ensemble of CNN Models for Parkinson’s Disease Detection Using DaTscan Images

Parkinson’s Disease (PD) is a progressive central nervous system disorder that is caused due to the neural degeneration mainly in the substantia nigra in the brain. It is responsible for the decline of various motor functions due to the loss of dopamine-producing neurons. Tremors in hands is usually the initial symptom, followed by rigidity, bradykinesia, postural instability, and impaired balance. Proper diagnosis and preventive treatment can help patients improve their quality of life. We have proposed an ensemble of Deep Learning (DL) models to predict Parkinson’s using DaTscan images. Initially, we have used four DL models, namely, VGG16, ResNet50, Inception-V3, and Xception, to classify Parkinson’s disease. In the next stage, we have applied a Fuzzy Fusion logic-based ensemble approach to enhance the overall result of the classification model. The proposed model is assessed on a publicly available database provided by the Parkinson’s Progression Markers Initiative (PPMI). The achieved recognition accuracy, Precision, Sensitivity, Specificity, F1-score from the proposed model are 98.45%, 98.84%, 98.84%, 97.67%, and 98.84%, respectively which are higher than the individual model. We have also developed a Graphical User Interface (GUI)-based software tool for public use that instantly detects all classes using Magnetic Resonance Imaging (MRI) with reasonable accuracy. The proposed method offers better performance compared to other state-of-the-art methods in detecting PD. The developed GUI-based software tool can play a significant role in detecting the disease in real-time.

Mining imaging and clinical data with machine learning approaches for the diagnosis and early detection of Parkinson's disease

Parkinson’s disease (PD) is a common, progressive, and currently incurable neurodegenerative movement disorder. The diagnosis of PD is challenging, especially in the differential diagnosis of parkinsonism and in early PD detection. Due to the advantages of machine learning such as learning complex data patterns and making inferences for individuals, machine-learning techniques have been increasingly applied to the diagnosis of PD, and have shown some promising results. Machine-learning-based imaging applications have made it possible to help differentiate parkinsonism and detect PD at early stages automatically in a number of neuroimaging studies. Comparative studies have shown that machine-learning-based SPECT image analysis applications in PD have outperformed conventional semi-quantitative analysis in detecting PD-associated dopaminergic degeneration, performed comparably well as experts’ visual inspection, and helped improve PD diagnostic accuracy of radiologists. Using combined multi-modal (imaging and clinical) data in these applications may further enhance PD diagnosis and early detection. To integrate machine-learning-based diagnostic applications into clinical systems, further validation and optimization of these applications are needed to make them accurate and reliable. It is anticipated that machine-learning techniques will further help improve differential diagnosis of parkinsonism and early detection of PD, which may reduce the error rate of PD diagnosis and help detect PD at pre-motor stage to make it possible for early treatments (e.g., neuroprotective treatment) to slow down PD progression, prevent severe motor symptoms from emerging, and relieve patients from suffering.

The impact of clinical scales in Parkinson’s disease: a systematic review

Background

Parkinson’s disease is one of the non-curable diseases and occurs by the prominent loss of neurotransmitter (dopamine) in substantia nigra pars compacta (SNpc). The main cause behind this is not yet identified and even its diagnosis is very intricate phase due to non-identified onset symptoms. Despite the fact that PD has been extensively researched over the decades, and various algorithms and strategies for early recognition and avoiding misdiagnosis have been published. The objective of this article is to focus on the current scenario and to explore the involvement of various clinical diagnostic scales in the detection of PD.

Method

An exhaustive literature review is conducted to synthesize the earlier work in this area, and the articles were searched using different keywords like Parkinson disease, motor/non-motor, treatment, diagnosis, scales, PPMI, etc., in all repositories such as Google scholar, Scopus, Elsevier, PubMed and many more. From the year 2017 to 2021, a total of 451 publications were scanned, but only 24 studies were chosen for a review process.

Findings

Mostly as clinical tools, UPDRS and HY scales are commonly used and even there are many other scales which can be helpful in detection of symptoms such as depression, anxiety, sleepiness, apathy, smell, anhedonia, fatigue, pain, etc., that affect the QoL of pateint. The recognition of non-motor manifests is typically very difficult than motor signs.

Conclusion

This study can give the beneficial research paths at an early stage diagnosis by focusing on frequent inspection of daily activities, interactions, and routine, which may also give a plethora of information on status changes, directing self-reformation, and clinical therapy.

Self-normalized Classification of Parkinson's Disease DaTscan Images

Classifying SPECT images requires a preprocessing step which normalizes the images using a normalization region. The choice of the normalization region is not standard, and using different normalization regions introduces normalization region-dependent variability. This paper mathematically analyzes the effect of the normalization region to show that normalized-classification is exactly equivalent to a subspace separation of the half rays of the images under multiplicative equivalence. Using this geometry, a new self-normalized classification strategy is proposed. This strategy eliminates the normalizing region altogether. The theory is used to classify DaTscan images of 365 Parkinson's disease (PD) subjects and 208 healthy control (HC) subjects from the Parkinson's Progression Marker Initiative (PPMI). The theory is also used to understand PD progression from baseline to year 4.

Early Prediction of Parkinson’s Disease from Brain MRI Images Using Convolutional Neural Network

The early diagnosis of Parkinson’s Disease (PD) is a challenging practice for doctors. Currently, there are no separate diagnostics and tests to be done to predict onset PD. However, the PD can be predicted through repeated clinical trials and tests. Sometimes, early prediction of PD can become tedious based on trials and tests. The computer-aided prediction will help medical professionals predict PD accurately during one’s onset stages to improve the PD patients’ quality of life. Hence, early prediction of PD is essential. In this article, Convolution Neural Networks (CNN) is proposed to classify PD patients and healthy individuals. The brain MRI images are given as input for the proposed methodology. The CNN deep neural network will first extract the features from the images. Then, it will classify the PD patients and healthy individuals from the extracted features. The automatic feature extraction will improve the accuracy of the classifier and reduce human error. The brain MRI images are taken from the PPMI dataset for experimentation. The sensitivity, specificity, and accuracy are calculated to assess the performance of the proposed methodology. The loss is also calculated to verify the performance of the classifier. It is observed that the CNN classifier has produced a higher accuracy of more than 98% in classifying PD patients and healthy individuals when compared to multi-layer perceptron deep learning.

Machine Learning for the Diagnosis of Parkinson's Disease: A Review of Literature

Diagnosis of Parkinson's disease (PD) is commonly based on medical observations and assessment of clinical signs, including the characterization of a variety of motor symptoms. However, traditional diagnostic approaches may suffer from subjectivity as they rely on the evaluation of movements that are sometimes subtle to human eyes and therefore difficult to classify, leading to possible misclassification. In the meantime, early non-motor symptoms of PD may be mild and can be caused by many other conditions. Therefore, these symptoms are often overlooked, making diagnosis of PD at an early stage challenging. To address these difficulties and to refine the diagnosis and assessment procedures of PD, machine learning methods have been implemented for the classification of PD and healthy controls or patients with similar clinical presentations (e.g., movement disorders or other Parkinsonian syndromes). To provide a comprehensive overview of data modalities and machine learning methods that have been used in the diagnosis and differential diagnosis of PD, in this study, we conducted a literature review of studies published until February 14, 2020, using the PubMed and IEEE Xplore databases. A total of 209 studies were included, extracted for relevant information and presented in this review, with an investigation of their aims, sources of data, types of data, machine learning methods and associated outcomes. These studies demonstrate a high potential for adaptation of machine learning methods and novel biomarkers in clinical decision making, leading to increasingly systematic, informed diagnosis of PD.

A review of the application of machine learning in molecular imaging

Molecular imaging (MI) is a science that uses imaging methods to reflect the changes of molecular level in living state and conduct qualitative and quantitative studies on its biological behaviors in imaging. Optical molecular imaging (OMI) and nuclear medical imaging are two key research fields of MI. OMI technology refers to the optical information generated by the imaging target (such as tumors) due to drug intervention and other reasons. By collecting the optical information, researchers can track the motion trajectory of the imaging target at the molecular level. Owing to its high specificity and sensitivity, OMI has been widely used in preclinical research and clinical surgery. Nuclear medical imaging mainly detects ionizing radiation emitted by radioactive substances. It can provide molecular information for early diagnosis, effective treatment and basic research of diseases, which has become one of the frontiers and hot topics in the field of medicine in the world today. Both OMI and nuclear medical imaging technology require a lot of data processing and analysis. In recent years, artificial intelligence technology, especially neural network-based machine learning (ML) technology, has been widely used in MI because of its powerful data processing capability. It provides a feasible strategy to deal with large and complex data for the requirement of MI. In this review, we will focus on the applications of ML methods in OMI and nuclear medical imaging.

Distinctive regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative Parkinsonisms

PURPOSE

This study aimed to identify regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative parkinsonisms, using dopamine transporter single-photon emission computed tomography images.

MATERIAL AND METHODS

This study included 213 consecutive participants (Parkinson's disease [n = 111], dementia with Lewy bodies [n = 64], progressive supranuclear palsy with Richardson's syndrome [n = 18], and healthy participants [n = 20]) who underwent both magnetic resonance imaging and ¹²³I-labelled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single-photon emission computed tomography/computed tomography. Using normalized specific binding ratio images, we created voxel-wise regional asymmetry index images to identify the regional specific pattern of regional asymmetries in degenerative parkinsonisms.

RESULTS

Compared with healthy controls, patients with Parkinson's disease showed a regional asymmetry index increase in the nigrostriatal dopaminergic pathway, and those with dementia with Lewy bodies showed a regional asymmetry index increase confined to the bilateral caudate. Individuals with progressive supranuclear palsy exhibited a distinct regional asymmetry index increase in the pallido-subthalamic pathway. Notably, the regional asymmetry index increase in the subthalamic nucleus was significantly greater in progressive supranuclear palsy than in Parkinson's disease.

CONCLUSION

The current study revealed distinctive regional asymmetry in dopaminergic and serotoninergic dysfunction in degenerative parkinsonisms. The present findings highlight the potential application of visual diagnosis in degenerative parkinsonisms.

Classification of the Multiple Stages of Parkinson's Disease by a Deep Convolution Neural Network Based on 99mTc-TRODAT-1 SPECT Images

Single photon emission computed tomography (SPECT) has been employed to detect Parkinson's disease (PD). However, analysis of the SPECT PD images was mostly based on the region of interest (ROI) approach. Due to limited size of the ROI, especially in the multi-stage classification of PD, this study utilizes deep learning methods to establish a multiple stages classification model of PD. In the retrospective study, the 99mTc-TRODAT-1 was used for brain SPECT imaging. A total of 202 cases were collected, and five slices were selected for analysis from each subject. The total number of images was thus 1010. According to the Hoehn and Yahr Scale standards, all the cases were divided into healthy, early, middle, late four stages, and HYS I~V six stages. Deep learning is compared with five convolutional neural networks (CNNs). The input images included grayscale and pseudo color of two types. The training and validation sets were 70% and 30%. The accuracy, recall, precision, F-score, and Kappa values were used to evaluate the models' performance. The best accuracy of the models based on grayscale and color images in four and six stages were 0.83 (AlexNet), 0.85 (VGG), 0.78 (DenseNet) and 0.78 (DenseNet).

A Shape Approximation for Medical Imaging Data

This study proposes a shape approximation approach to portray the regions of interest (ROI) from medical imaging data. An effective algorithm to achieve an optimal approximation is proposed based on the framework of Particle Swarm Optimization. The convergence of the proposed algorithm is derived under mild assumptions on the selected family of shape equations. The issue of detecting Parkinson’s disease (PD) based on the Tc-99m TRODAT-1 brain SPECT/CT images of 634 subjects, with 305 female and an average age of 68.3 years old from Kaohsiung Chang Gung Memorial Hospital, Taiwan, is employed to demonstrate the proposed procedure by fitting optimal ellipse and cashew-shaped equations in the 2D and 3D spaces, respectively. According to the visual interpretation of 3 experienced board-certified nuclear medicine physicians, 256 subjects are determined to be abnormal, 77 subjects are potentially abnormal, 174 are normal, and 127 are nearly normal. The coefficients of the ellipse and cashew-shaped equations, together with some well-known features of PD existing in the literature, are employed to learn PD classifiers under various machine learning approaches. A repeated hold-out with 100 rounds of 5-fold cross-validation and stratified sampling scheme is adopted to investigate the classification performances of different machine learning methods and different sets of features. The empirical results reveal that our method obtains 0.88 ± 0.04 classification accuracy, 0.87 ± 0.06 sensitivity, and 0.88 ± 0.08 specificity for test data when including the coefficients of the ellipse and cashew-shaped equations. Our findings indicate that more constructive and useful features can be extracted from proper mathematical representations of the 2D and 3D shapes for a specific ROI in medical imaging data, which shows their potential for improving the accuracy of automated PD identification.

An Explainable Machine Learning Model for Early Detection of Parkinson's Disease using LIME on DaTSCAN Imagery

Parkinson's Disease (PD) is a degenerative and progressive neurological condition. Early diagnosis can improve treatment for patients and is performed through dopaminergic imaging techniques like the SPECT DaTSCAN. In this study, we propose a machine learning model that accurately classifies any given DaTSCAN as having Parkinson's disease or not, in addition to providing a plausible reason for the prediction. This kind of reasoning is done through the use of visual indicators generated using Local Interpretable Model-Agnostic Explainer (LIME) methods. DaTSCANs were drawn from the Parkinson's Progression Markers Initiative database and trained on a CNN (VGG16) using transfer learning, yielding an accuracy of 95.2%, a sensitivity of 97.5%, and a specificity of 90.9%. Keeping model interpretability of paramount importance, especially in the healthcare field, this study utilises LIME explanations to distinguish PD from non-PD, using visual superpixels on the DaTSCANs. It could be concluded that the proposed system, in union with its measured interpretability and accuracy may effectively aid medical workers in the early diagnosis of Parkinson's Disease.

Diffusion Tensor Imaging in Parkinson's Disease and Parkinsonian Syndrome: A Systematic Review

Diffusion tensor imaging (DTI) allows measuring fractional anisotropy and similar microstructural indices of the brain white matter. Lower than normal fractional anisotropy as well as higher than normal diffusivity is associated with loss of microstructural integrity and neurodegeneration. Previous DTI studies in Parkinson's disease (PD) have demonstrated abnormal fractional anisotropy in multiple white matter regions, particularly in the dopaminergic nuclei and dopaminergic pathways. However, DTI is not considered a diagnostic marker for the earliest Parkinson's disease since anisotropic alterations present a temporally divergent pattern during the earliest Parkinson's course. This article reviews a majority of clinically employed DTI studies in PD, and it aims to prove the utilities of DTI as a marker of diagnosing PD, correlating clinical symptomatology, tracking disease progression, and treatment effects. To address the challenge of DTI being a diagnostic marker for early PD, this article also provides a comparison of the results from a longitudinal, early stage, multicenter clinical cohort of Parkinson's research with previous publications. This review provides evidences of DTI as a promising marker for monitoring PD progression and classifying atypical PD types, and it also interprets the possible pathophysiologic processes under the complex pattern of fractional anisotropic changes in the first few years of PD. Recent technical advantages, limitations, and further research strategies of clinical DTI in PD are additionally discussed.

Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT

Purpose

The dopamine transporter (DAT) serves as biomarker for parkinsonian syndromes. DAT can be measured in vivo with single-photon emission computed tomography (SPECT) and positron emission tomography (PET). DAT-SPECT is the current clinical molecular imaging standard. However, PET has advantages over SPECT measurements, and PET radioligands with the necessary properties for clinical applications are on the rise. Therefore, it is time to review the role of DAT imaging with SPECT compared to PET.

Methods

PubMed and Web of Science were searched for relevant literature of the previous 10 years. Four topics for comparison were used: diagnostic accuracy, quantitative accuracy, logistics, and flexibility.

Results

There are a few studies directly comparing DAT-PET and DAT-SPECT. PET and SPECT both perform well in discriminating neurodegenerative from non-neurodegenerative parkinsonism. Clinical DAT-PET imaging seems feasible only recently, thanks to simplified DAT assessments and better availability of PET radioligands and systems. The higher resolution of PET makes more comprehensive assessments of disease progression in the basal ganglia possible. Additionally, it has the possibility of multimodal target assessment.

Conclusion

DAT-SPECT is established for differentiating degenerative from non-degenerative parkinsonism. For further differentiation within neurodegenerative Parkinsonian syndromes, DAT-PET has essential benefits. Nowadays, because of wider availability of PET systems and radioligand production centers, and the possibility to use simplified quantification methods, DAT-PET imaging is feasible for clinical use. Therefore, DAT-PET needs to be considered for a more active role in the clinic to take a step forward to a more comprehensive understanding and assessment of Parkinson’s disease.

Morphological Characterization of Functional Brain Imaging by Isosurface Analysis in Parkinson’s Disease

Finding new biomarkers to model Parkinson’s Disease (PD) is a challenge not only to help discerning between Healthy Control (HC) subjects and patients with potential PD but also as a way to measure quantitatively the loss of dopaminergic neurons mainly concentrated at substantia nigra. Within this context, this work presented here tries to provide a set of imaging features based on morphological characteristics extracted from I[Formula: see text]-Ioflupane SPECT scans to discern between HC and PD participants in a balanced set of [Formula: see text] scans from Parkinson’s Progression Markers Initiative (PPMI) database. These features, obtained from isosurfaces of each scan at different intensity levels, have been classified through the use of classical Machine Learning classifiers such as Support-Vector-Machines (SVM) or Naïve Bayesian and compared with the results obtained using a Multi-Layer Perceptron (MLP).

The proposed system, based on a Mann–Whitney–Wilcoxon U-Test for feature selection and the SVM approach, yielded a [Formula: see text] balanced accuracy when the performance was evaluated using a [Formula: see text]-fold cross-validation. This proves the reliability of these biomarkers, especially those related to sphericity, center of mass, number of vertices, 2D-projected perimeter or the 2D-projected eccentricity, among others, but including both internal and external isosurfaces.

Non-motor Clinical and Biomarker Predictors Enable High Cross-Validated Accuracy Detection of Early PD but Lesser Cross-Validated Accuracy Detection of Scans Without Evidence of Dopaminergic Deficit

Background: Early stage (preclinical) detection of Parkinson's disease (PD) remains challenged yet is crucial to both differentiate it from other disorders and facilitate timely administration of neuroprotective treatment as it becomes available. Objective: In a cross-validation paradigm, this work focused on two binary predictive probability analyses: classification of early PD vs. controls and classification of early PD vs. SWEDD (scans without evidence of dopamine deficit). It was hypothesized that five distinct model types using combined non-motor and biomarker features would distinguish early PD from controls with > 80% cross-validated (CV) accuracy, but that the diverse nature of the SWEDD category would reduce early PD vs. SWEDD CV classification accuracy and alter model-based feature selection. Methods: Cross-sectional, baseline data was acquired from the Parkinson's Progressive Markers Initiative (PPMI). Logistic regression, general additive (GAM), decision tree, random forest and XGBoost models were fitted using non-motor clinical and biomarker features. Randomized train and test data partitions were created. Model classification CV performance was compared using the area under the curve (AUC), sensitivity, specificity and the Kappa statistic. Results: All five models achieved >0.80 AUC CV accuracy to distinguish early PD from controls. The GAM (CV AUC 0.928, sensitivity 0.898, specificity 0.897) and XGBoost (CV AUC 0.923, sensitivity 0.875, specificity 0.897) models were the top classifiers. Performance across all models was consistently lower in the early PD/SWEDD analyses, where the highest performing models were XGBoost (CV AUC 0.863, sensitivity 0.905, specificity 0.748) and random forest (CV AUC 0.822, sensitivity 0.809, specificity 0.721). XGBoost detection of non-PD SWEDD matched 1-2 years curated diagnoses in 81.25% (13/16) cases. In both early PD/control and early PD/SWEDD analyses, and across all models, hyposmia was the single most important feature to classification; rapid eye movement behavior disorder (questionnaire) was the next most commonly high ranked feature. Alpha-synuclein was a feature of import to early PD/control but not early PD/SWEDD classification and the Epworth Sleepiness scale was antithetically important to the latter but not former. Interpretation: Non-motor clinical and biomarker variables enable high CV discrimination of early PD vs. controls but are less effective discriminating early PD from SWEDD.

A novel semi-supervised multi-view clustering framework for screening Parkinson's disease

In recent years, there are many research cases for the diagnosis of Parkinson's disease (PD) with the brain magnetic resonance imaging (MRI) by utilizing the traditional unsupervised machine learning methods and the supervised deep learning models. However, unsupervised learning methods are not good at extracting accurate features among MRIs and it is difficult to collect enough data in the field of PD to satisfy the need of training deep learning models. Moreover, most of the existing studies are based on single-view MRI data, of which data characteristics are not sufficient enough. In this paper, therefore, in order to tackle the drawbacks mentioned above, we propose a novel semi-supervised learning framework called Semi-supervised Multi-view learning Clustering architecture technology (SMC). The model firstly introduces the sliding window method to grasp different features, and then uses the dimensionality reduction algorithms of Linear Discriminant Analysis (LDA) to process the data with different features. Finally, the traditional single-view clustering and multi-view clustering methods are employed on multiple feature views to obtain the results. Experiments show that our proposed method is superior to the state-of-art unsupervised learning models on the clustering effect. As a result, it may be noted that, our work could contribute to improving the effectiveness of identifying PD by previous labeled and subsequent unlabeled medical MRI data in the realistic medical environment.

Effect of Parkinsonism on Proximal Unstructured Movement Captured by Inertial Sensors

In this study, we endeavour to measure characteristic movements of patients with Parkinson's disease (PD). Our eventual aim is to obtain the severity of these exhibited movements entirely based on measurements conducted in un-clinical environments. Indeed, we investigate the feasibility of capturing such un-structured movements using wearable sensors. In particular, as Bradykinesia and axial Bradykinesia are vital characteristics yet challenging to measure, we design a test system of Inertial Measurement (IM) based wearable sensors in order to capture the affected movements of the back. The study evaluated the characteristics of PD patients during the unstructured activities. Our analysis captured back flexibility based on frequency information of the sensors attached to the human back. Satisfactory classification in each test confirms that this testing system can identify as well as evaluate PD patients using a minimal number of sensors during these unstructured movements. Our objective is to enhance the uptake and promote the use of wearable sensors in longer term monitoring scenarios relevant to non-clinical environments. Thus, we envisage clinicians monitoring the progress due to the treatment of patients residing in their homes assisted by sensors with enhanced wearability.

Exploring Active Learning Based on Representativeness and Uncertainty for Biomedical Data Classification

Nowadays, there is an abundance of biomedical data, such as images and genetic sequences, among others. However, there is a lack of annotation to such volume of data, due to the high costs involved to perform this task. Thus, it is mandatory to develop techniques to ease the burden of human annotation. To reach such goal active learning strategies can be applied. However, the state-of-the-art active learning methods, generally, are not feasible to lead with real-world datasets. Another important issue, that is generally neglected by these methods, is related to the conception that the classifier tends to learn more and more at each iteration. Their adopted selection criteria do not properly exploit the knowledge of the classifier. Therefore, in this paper, we propose the use of an active learning approach, in order to leverage the learning process, including the proposal of a novel active learning strategy. The main difference of our proposed strategy is related to the participation of the classifier in an extremely active way in its learning process. So, we can better maximize and prioritize the knowledge that is obtained by the classifier at each iteration, making use of this knowledge in a more appropriate and useful way when selecting more informative samples. To do so, in our selection criteria, we give significant importance to the classifications suggested by the classifier. In addition, jointly with the participation and the knowledge of the classifier, we consider both uncertainty and representativeness criteria through a fine-grained analysis of the samples. Experimental results show that our novel active learning approach outperforms state-of-the-art active learning methods, considering several supervised classifiers. Hence, dealing with real dataset problems in a better way, equalizing the tradeoff between annotation task and higher accuracy rates.

Artificial intelligence in the diagnosis of Parkinson's disease from ioflupane-123 single-photon emission computed tomography dopamine transporter scans using transfer learning

OBJECTIVE

The objective of this study was to identify the extent to which artificial intelligence could be used in the diagnosis of Parkinson's disease from ioflupane-123 (¹²³I) single-photon emission computed tomography (SPECT) dopamine transporter scans using transfer learning.

MATERIALS AND METHODS

A data set of 54 normal and 54 abnormal ¹²³I SPECT scans was amplified 44-fold using a process of image augmentation. This resulted in a training set of 2376 normal and 2376 abnormal images. This was used to retrain the top layer of the Inception v3 network. The resulting neural network functioned as a classifier for new ¹²³I SPECT scans as either normal or abnormal. A completely separate set of 45 ¹²³I SPECT scans were used for final testing of the network.

RESULTS

The area under the receiver-operator curve in final testing was 0.87. This corresponded to a test sensitivity of 96.3%, a specificity of 66.7%, a positive predictive value of 81.3% and a negative predictive value of 92.3%, using an optimum diagnostic threshold.

CONCLUSION

This study has provided proof of concept for the use of transfer learning, from convolutional neural networks pretrained on nonmedical images, for the interpretation of ¹²³I SPECT scans. This has been shown to be possible in this study even with a very small sample size. This technique is likely to be applicable to many areas of diagnostic imaging.

Key Marker Selection for the Detection of Early Parkinson' s Disease using Importance-Driven Models

The detection of early Parkinson' s disease (PD) is crucial for PD management. Most of previous efforts on PD diagnosis focus more on improving PD detection accuracies by trying using features from more modalities, which results in a common question: is it true that the more features available, the better the performance of the diagnosis system? This paper proposes an importance-driven approach for the detection of PD. The importance of features based on gradient boosting is firstly learned. The ranked features based on feature importance are input to a progressive learning pipeline to find key features of PD. The experiment results show that a comparable PD classification performance can be obtained with much less key features and therefore fewer modalities of tests are required. Such findings have critical socioeconomic values.

Comparison of machine learning and semi-quantification algorithms for (I123)FP-CIT classification: the beginning of the end for semi-quantification?

BACKGROUND

Semi-quantification methods are well established in the clinic for assisted reporting of (I123) Ioflupane images. Arguably, these are limited diagnostic tools. Recent research has demonstrated the potential for improved classification performance offered by machine learning algorithms. A direct comparison between methods is required to establish whether a move towards widespread clinical adoption of machine learning algorithms is justified. This study compared three machine learning algorithms with that of a range of semi-quantification methods, using the Parkinson's Progression Markers Initiative (PPMI) research database and a locally derived clinical database for validation. Machine learning algorithms were based on support vector machine classifiers with three different sets of features: Voxel intensities Principal components of image voxel intensities Striatal binding radios from the putamen and caudate. Semi-quantification methods were based on striatal binding ratios (SBRs) from both putamina, with and without consideration of the caudates. Normal limits for the SBRs were defined through four different methods: Minimum of age-matched controls Mean minus 1/1.5/2 standard deviations from age-matched controls Linear regression of normal patient data against age (minus 1/1.5/2 standard errors) Selection of the optimum operating point on the receiver operator characteristic curve from normal and abnormal training data Each machine learning and semi-quantification technique was evaluated with stratified, nested 10-fold cross-validation, repeated 10 times.

RESULTS

The mean accuracy of the semi-quantitative methods for classification of local data into Parkinsonian and non-Parkinsonian groups varied from 0.78 to 0.87, contrasting with 0.89 to 0.95 for classifying PPMI data into healthy controls and Parkinson's disease groups. The machine learning algorithms gave mean accuracies between 0.88 to 0.92 and 0.95 to 0.97 for local and PPMI data respectively.

CONCLUSIONS

Classification performance was lower for the local database than the research database for both semi-quantitative and machine learning algorithms. However, for both databases, the machine learning methods generated equal or higher mean accuracies (with lower variance) than any of the semi-quantification approaches. The gain in performance from using machine learning algorithms as compared to semi-quantification was relatively small and may be insufficient, when considered in isolation, to offer significant advantages in the clinical context.